Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 6
1997 13
1998 17
1999 23
2000 34
2001 56
2002 72
2003 111
2004 110
2005 144
2006 135
2007 147
2008 178
2009 153
2010 165
2011 189
2012 140
2013 130
2014 127
2015 118
2016 94
2017 106
2018 83
2019 67
2020 55
2021 41
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

2,210 results
Results by year
Filters applied: . Clear all
Page 1
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.
Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM; SPARCL Committees and Investigators. Szarek M, et al. J Am Coll Cardiol. 2020 May 5;75(17):2110-2118. doi: 10.1016/j.jacc.2020.03.015. Epub 2020 Mar 16. J Am Coll Cardiol. 2020. PMID: 32194196 Free article. Clinical Trial.
Atorvastatin reduced the first occurrence of stroke and the first occurrence of a composite of vascular events. ...Over 6 years, an estimated 20 vascular events per 100 participants were avoided with atorvastatin treatment. CONCLUSIONS: In participants with recent s
Atorvastatin reduced the first occurrence of stroke and the first occurrence of a composite of vascular events. ...Over 6 years, an e
Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial.
Jiang R, Zhao S, Wang R, Feng H, Zhang J, Li X, Mao Y, Yuan X, Fei Z, Zhao Y, Yu X, Poon WS, Zhu X, Liu N, Kang D, Sun T, Jiao B, Liu X, Yu R, Zhang J, Gao G, Hao J, Su N, Yin G, Zhu X, Lu Y, Wei J, Hu J, Hu R, Li J, Wang D, Wei H, Tian Y, Lei P, Dong JF, Zhang J. Jiang R, et al. JAMA Neurol. 2018 Nov 1;75(11):1338-1346. doi: 10.1001/jamaneurol.2018.2030. JAMA Neurol. 2018. PMID: 30073290 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomly assigned to receive either 20 mg of atorvastatin or placebo daily for 8 weeks and were followed up for an additional 16 weeks. ...The baseline HV and clinical presentations were similar between patients who were taking atorvastatin
INTERVENTIONS: Patients were randomly assigned to receive either 20 mg of atorvastatin or placebo daily for 8 weeks and were followed …
N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects.
Wood FA, Howard JP, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, Rajkumar CA, Connolly S, Cegla J, Stride C, Sever P, Norton C, Thom SAM, Shun-Shin MJ, Francis DP. Wood FA, et al. N Engl J Med. 2020 Nov 26;383(22):2182-2184. doi: 10.1056/NEJMc2031173. Epub 2020 Nov 15. N Engl J Med. 2020. PMID: 33196154 Clinical Trial. No abstract available.
Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
Berwanger O, Santucci EV, de Barros E Silva PGM, Jesuíno IA, Damiani LP, Barbosa LM, Santos RHN, Laranjeira LN, Egydio FM, Borges de Oliveira JA, Dall Orto FTC, Beraldo de Andrade P, Bienert IRC, Bosso CE, Mangione JA, Polanczyk CA, Sousa AGMR, Kalil RAK, Santos LM, Sposito AC, Rech RL, Sousa ACS, Baldissera F, Nascimento BR, Giraldez RRCV, Cavalcanti AB, Pereira SB, Mattos LA, Armaganijan LV, Guimarães HP, Sousa JEMR, Alexander JH, Granger CB, Lopes RD; SECURE-PCI Investigators. Berwanger O, et al. JAMA. 2018 Apr 3;319(13):1331-1340. doi: 10.1001/jama.2018.2444. JAMA. 2018. PMID: 29525821 Free PMC article. Clinical Trial.
All patients received 40 mg of atorvastatin for 30 days starting 24 hours after the second dose of study medication. ...No cases of hepatic failure were reported; 3 cases of rhabdomyolysis were reported in the placebo group (0.1%) and 0 in the atorvastatin group. CO …
All patients received 40 mg of atorvastatin for 30 days starting 24 hours after the second dose of study medication. ...No cases of h …
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, Häner J, Gencer B, Crljenica C, Amini P, Deckarm O, Iglesias JF, Räber L, Heg D, Mach F. Koskinas KC, et al. J Am Coll Cardiol. 2019 Nov 19;74(20):2452-2462. doi: 10.1016/j.jacc.2019.08.010. Epub 2019 Aug 31. J Am Coll Cardiol. 2019. PMID: 31479722 Free article. Clinical Trial.
Patients were randomly assigned 1:1 to receive subcutaneous evolocumab 420 mg or matching placebo, administered in-hospital and after 4 weeks, on top of atorvastatin 40 mg. The primary endpoint was percentage change in calculated LDL-C from baseline to 8 weeks. ...
Patients were randomly assigned 1:1 to receive subcutaneous evolocumab 420 mg or matching placebo, administered in-hospital and after 4 week …
Body-Weight Fluctuations and Outcomes in Coronary Disease.
Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Bangalore S, et al. N Engl J Med. 2017 Apr 6;376(14):1332-1340. doi: 10.1056/NEJMoa1606148. N Engl J Med. 2017. PMID: 28379800 Free article. Clinical Trial.
METHODS: We determined intraindividual fluctuations in body weight from baseline weight and follow-up visits and performed a post hoc analysis of the Treating to New Targets trial, which involved assessment of the efficacy and safety of lowering low-density lipoprotein cholestero …
METHODS: We determined intraindividual fluctuations in body weight from baseline weight and follow-up visits and performed a post hoc analys …
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Gupta A, Mackay J, Whitehouse A, Godec T, Collier T, Pocock S, Poulter N, Sever P. Gupta A, et al. Lancet. 2018 Sep 29;392(10153):1127-1137. doi: 10.1016/S0140-6736(18)31776-8. Epub 2018 Aug 26. Lancet. 2018. PMID: 30158072 Free article. Clinical Trial.
Of these patients, those who had total cholesterol of 65 mmol/L or lower and no previous lipid-lowering treatment underwent further randomisation to receive either atorvastatin or placebo as part of the lipid-lowering arm (LLA) of ASCOT. ...INTERPRETATION: Our findings sho …
Of these patients, those who had total cholesterol of 65 mmol/L or lower and no previous lipid-lowering treatment underwent further randomis …
Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial.
Fotso Soh J, Torres-Platas SG, Beaulieu S, Mantere O, Platt R, Mucsi I, Saury S, Renaud S, Levinson A, Andreazza AC, Mulsant BH, Müller D, Schaffer A, Dols A, Cervantes P, Low NC, Herrmann N, Christensen BM, Trepiccione F, Rajji T, Rej S. Fotso Soh J, et al. BMC Psychiatry. 2018 Jul 16;18(1):227. doi: 10.1186/s12888-018-1793-9. BMC Psychiatry. 2018. PMID: 30012135 Free PMC article. Clinical Trial.
In this current paper, we describe the methodology of a randomized controlled trial (RCT) to treat lithium-induced NDI using atorvastatin. METHODS: We will conduct a 12-week, double-blind placebo-controlled RCT of atorvastatin for lithium-induced NDI at McGill Unive …
In this current paper, we describe the methodology of a randomized controlled trial (RCT) to treat lithium-induced NDI using atorvastatin
A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis.
Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM; TRACE RA Consortium. Kitas GD, et al. Arthritis Rheumatol. 2019 Sep;71(9):1437-1449. doi: 10.1002/art.40892. Epub 2019 Jul 22. Arthritis Rheumatol. 2019. PMID: 30983166 Free PMC article. Clinical Trial.
The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVEs in RA patients. ...CONCLUSION: Atorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholest …
The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of …
To study the effect of high dose Atorvastatin 40mg versus 80mg in patients with dyslipidemia.
Agrawal D, Manchanda SC, Sawhney JPS, Kandpal B, Jain R, Mehta A, Mohanty A, Passey R, Makhija A, Sharma MK. Agrawal D, et al. Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S8-S12. doi: 10.1016/j.ihj.2018.01.034. Epub 2018 Jan 31. Indian Heart J. 2018. PMID: 30595326 Free PMC article. Clinical Trial.
They were randomly divided into 2 groups of 120 each. Group A consisted patients who received Atorvastatin 40mg daily and Group B Atorvastatin 80mg daily. The follow up period was 6 months. ...While Atorvastatin 80mg results in LDL reduction as 50.1115.85 &am …
They were randomly divided into 2 groups of 120 each. Group A consisted patients who received Atorvastatin 40mg daily and Group B …
2,210 results